Faeth Therapeutics (FTH) news
Recent news
Faeth Therapeutics, Inc: Needham initiates coverage with buy rating; price target $56
Citizens has initiated coverage of Faeth Therapeutics (FTH) with an "Outperform" rating and a price target of $51, according to a report from TheFly[14]. This follows a series of recent analyst actions, including Raymond James and Oppenheimer, who also assigned "Outperform" ratings with price…
AInvest Wire · Aug 21, 2026Faeth Therapeutics announces FDA grant of fast track
AInvest Wire · Aug 17, 2026Faeth Therapeutics, Inc: Oppenheimer initiates coverage with outperform rating; price target $60
Oppenheimer & Co. has initiated coverage of Faeth Therapeutics, Inc. (NASDAQ: FAET) with an "outperform" rating and a price target of $60 per share, according to a recent report[1]. The firm cited the company's progress in its clinical pipeline and potential for long-term growth as key factors in…
AInvest Wire · Jul 28, 2026Faeth Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jul 3, 2026Faeth Therapeutics, Inc.: H.C. Wainwright initiates coverage with buy rating
H.C. Wainwright & Co. has initiated coverage of Faeth Therapeutics, Inc. (NASDAQ: FAET) with a "Buy" rating, citing the company's progress in its clinical pipeline and [strategic focus on rare diseases][引用越界:1]. The firm highlighted Faeth's lead candidate, FT-101, currently in Phase II trials for…
AInvest Wire · Jun 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.